40-Year-Old Woman Denied Cancer Medication Announces Her Passing

The death of a 40-year-old woman has occurred, following her denial of a cancer drug that could extend life, due to its unavailability in Wales. Rachel Davies, a Swansea resident diagnosed with secondary breast cancer that had metastasized to her bones, back, pelvis, and neck, had pre-scheduled a social media announcement of her passing. On Facebook, she stated: “If you’re reading this, then it means I’m no longer here, I can’t say to a better place as that is impossible!” The drug Enhertu is accessible in Scotland and 19 other European nations but not in the remaining parts of the UK. A spokesperson for the Welsh government indicated that their stance was based on independent recommendations from the health assessment body NICE, which deemed the drug too costly for NHS funding. Rachel’s post continued: “What a life I’ve had, and surprisingly, since cancer entered my life. “When I look through my photos, I’ve done and seen so much since cancer, and probably some of my best memories are from this period.””In so many ways, I have to thank it for learning how to live fully. What I wish is that everyone can experience the same but without needing cancer. Get out there, experience life fully, and wear that dress!!!” She further expressed: “I’m so sad to leave my family and friends, I wish I never had to go. “I’m so grateful to have had Charlie young so that I’ve watched him grow into the man he is today, I’m unbelievably proud of him. I am thankful I had the opportunity to have Kacey and Jacob in my life.””Lastly, I was blessed to meet the love of my life, my husband, and my best friend. I have no regrets, I have had a wonderful life.” Her message concluded: “So to all of you, don’t be sad I’ve gone. Live your life and live it well. Love, Rachel x” On average, Enhertu has the potential to extend the lives of patients with a particular form of incurable breast cancer by an additional six months. Breast Cancer Now, a charity that had voiced criticism regarding the decision to withhold the drug, issued a statement: “Rachel was a tireless campaigner for the drug Enhertu, and an incredible advocate for people living with secondary breast cancer.”We will miss you Rachel. Thank you for being such an important part of our campaigning work.” Last month, during her final chemotherapy treatment administered by the NHS, Rachel informed BBC Wales News that she believed the drug had a strong likelihood of efficacy for her specific HER2-low metastatic breast cancer. She stated, “I just want the chance, the chance to be able to live.” She added, “That’s why I’m doing this, for my son and my family, not just for me.” Further, she remarked, “My son’s 18… he’s faced with knowing that his mother is ultimately going to die soon.” An oncologist from the Swansea Bay health board, treating Rachel, sought specialist funding, but the request was denied. The health board had previously stated that it “carefully considers all requests for the funding of treatments that fall outside normal treatment protocols” and incorporates NICE recommendations into its decisions. In July, NICE opted against recommending the drug, citing its lack of cost-effectiveness and urging pharmaceutical companies to propose a more equitable price. The health board offered its condolences, stating: “We are very sorry to hear of Rachel’s loss and express our deepest sympathy to her family and friends.” Rachel’s family honored her strength and courage, commenting: “We are incredibly proud of our wonderful Rachel. She was the best of us.” They continued: “We’re incredibly proud of the campaigning she did, and the awareness she raised of secondary breast cancer and the need for Enhertu.” The family added: “The sadness we feel is tainted by the knowing that other families in Wales, Northern Ireland and England will go through this without access to the drug.” Their statement concluded: “We as a family are heartbroken.” NICE issued a statement: “We were sorry to hear about the death of Rachel Davies and our thoughts are with her family and loved ones”.”We were extremely disappointed that talks to reach a price agreement that would have made Enhertu available to around 1,000 women in England and Wales were not successful.” They further explained: “As we’ve always made clear, the fastest and only guaranteed way to get medicines like Enhertu to the patients who need them is for companies to offer a fair price.” NICE concluded: “Enhertu remains the only breast cancer treatment we’ve been unable to recommend for six years.” Copyright 2024 BBC. All rights reserved. The BBC is not responsible for the content of external sites. Information regarding their approach to external linking is available.